در هنگام جستجو کلمه در قسمت عنوان میتوانید کلمات مورد جستجو را با کاراکتر (-) جدا کنید.
کاربرد نوع شرط:
- جایگاه : پژوهشی
- مجله: Iranian Journal of Pharmaceutical Sciences
- نوع مقاله: Journal Article
- کلمات کلیدی: Biodistribution,Bone metastases,Radiopharmaceutical,DOTMP,Ytterbium-175
- چکیده:
- چکیده انگلیسی: Bone is the third most common site of metastatic disease. Bone pain is the major source of morbidity associated bone metastasis. Bone-seeking radiopharma- ceuticals have been applied for many years. The ability to simultaneously treat multiple sites of disease with a more probable therapeutic effect in earlier phases of metastatic disease is one of the advantages of radiopharmaceuticals. 175Yb is one of the radioisotopes with suitable properties for developing various nuclear medicine agents. Some of these proper properties include 4.2 days half-life, gamma-rays emitted, radionuclidic purity. Radiopharmaceuticals capable of targeting bone tumors generally use phosphonic acid functionality as the targeting moiety. In this direction cyclic tetraphosphonate, 1,4,7,10-tetraazacyclododecane-1,4,7,10 tetraaminomethylenephosphonate (DOTMP) has been labeled with 175YbCl3. Production, quality control and biodistribution studies of 175Yb-DOTMP were targeted in this study. 175Yb chloride with mean specific activity of 31 mCi/mg was obtained by thermal neutron flux (3×1013 n.cm-2.s-1) of a natural Yb2O3 sample (isotopic purity of 31.8% for 174Yb) in the Tehran Research Reactor (TRR). Radiolabeling was completed in one h by the addition of DOTMP at room temperature. The radiochemical purity was determined using ITLC and it was more than 98%. The results of biodistribution animal studies are excellent. It was rapidly taken up in the bone in 2 h after injection (ID/g%=3.92) and reminded after 4 d (ID/g%=3.91).
- انتشار مقاله: 15-09-1390
- نویسندگان: Laleh Safarzadeh,Mohammad Ghannadi-Maragheh,Akbar Anvari,Seyed Mahmoud Reza Aghamiri,Simindokht Shirvani-Arani,Ali Bahrami-Samani
- مشاهده
- جایگاه : پژوهشی
- مجله: Asia Oceania Journal of Nuclear Medicine and Biology
- نوع مقاله: Journal Article
- کلمات کلیدی: Bone pain palliation,Lu-177,TTHMP,Dosimetry
- چکیده:
- چکیده انگلیسی: Objective(s): Recently, bone-avid radiopharmaceuticals have been shown to have potential benefits for the treatment of widespread bone metastases. Although 177Lutriethylene tetramine hexa methylene phosphonic acid (abbreviated as 177Lu- TTHMP), as an agent for bone pain palliation, has been evaluated in previous studies, there are large discrepancies between the obtained results. In this study, production, quality control, biodistribution, and dose evaluation of 177Lu-TTHMP have been investigated and compared with the previously reported data.
Methods: TTHMP was synthesized and characterized, using spectroscopic methods. Radiochemical purity of the 177Lu-TTHMP complex was determined using instant thin-layer chromatography (ITLC) and high performance liquid chromatography (HPLC) methods. The complex was injected to wild-type rats and biodistribution was studied for 7 days. Preliminary dose evaluation was investigated based on
biodistribution data in rats.
Results: 177Lu was prepared with 2.6-3 GBq/mg specific activity and radionuclide purity of 99.98%. 177Lu-TTHMP was successfully prepared with high radiochemical purity (>99%). The complex showed rapid bone uptake, while accumulation in other organs was insignificant. Dosimetric results showed that all tissues received almost insignificant absorbed doses in comparison with bone tissues.
Conclusion: Based on the obtained results, this radiopharmaceutical can be a good candidate for bone pain palliation therapy in skeletal metastases.- انتشار مقاله: 23-01-1393
- نویسندگان: Samaneh Zolghadri,Hassan Yousefnia,Amir Reza Jalilian,Mohammad Ghannadi-maragheh
- مشاهده